The data of Wang W et al. provided the evidence that ferroptosis inducers sorafenib and erastin reduced FDX1 degradation and GSH synthesis to enhance elesclomol-Cu-induced cell death in liver cancer cells, suggesting a link between cuproptosis and ferroptosis in the therapy depending on metal element dysfunction (Wang W. et al., 2023). Here, FDX1 is linked to liver cancer.